BACKGROUND: HLA-B57, as well as cytotoxic T-lymphocyte (CTL) responses restricted by this allele, have been strongly associated with long-term non-progressive chronic HIV-1 infection. However, their impact on viral replication during acute HIV-1 infection is not known. METHODS: Clinical and immunological parameters during acute and early HIV-1 infection in individuals expressing HLA-B57 were assessed. HIV-1-specific T-cell responses were determined by peptide-specific interferon-gamma production measured using Elispot assay and flow-based intracellular cytokine quantification. RESULTS: Individuals expressing HLA-B57 presented significantly less frequently with symptomatic acute HIV-1 infection (4/116, 3.4%) than expected from the frequency of chronically infected individuals expressing this allele (43/446, 9.6%; P < 0.05). During acute infection, virus-specific CD8 T-cell responses were dominated by HLA-B57-restricted responses, with significantly broader (P < 0.02) and stronger (P < 0.03) responses restricted by HLA-B57 than restricted by all other co-expressed HLA class I alleles combined. Six out of nine individuals expressing HLA-B57 controlled HIV-1 viremia in the absence of therapy at levels < 5000 copies/ml (median, 515 copies/ml) during up to 29 months following acute infection. CONCLUSION: These data demonstrate that host genetic factors can influence the clinical manifestations of acute HIV-1 infection and provide a functional link between HLA-B57 and viral immune control.
BACKGROUND: HLA-B57, as well as cytotoxic T-lymphocyte (CTL) responses restricted by this allele, have been strongly associated with long-term non-progressive chronic HIV-1 infection. However, their impact on viral replication during acute HIV-1 infection is not known. METHODS: Clinical and immunological parameters during acute and early HIV-1 infection in individuals expressing HLA-B57 were assessed. HIV-1-specific T-cell responses were determined by peptide-specific interferon-gamma production measured using Elispot assay and flow-based intracellular cytokine quantification. RESULTS: Individuals expressing HLA-B57 presented significantly less frequently with symptomatic acute HIV-1 infection (4/116, 3.4%) than expected from the frequency of chronically infected individuals expressing this allele (43/446, 9.6%; P < 0.05). During acute infection, virus-specific CD8 T-cell responses were dominated by HLA-B57-restricted responses, with significantly broader (P < 0.02) and stronger (P < 0.03) responses restricted by HLA-B57 than restricted by all other co-expressed HLA class I alleles combined. Six out of nine individuals expressing HLA-B57 controlled HIV-1 viremia in the absence of therapy at levels < 5000 copies/ml (median, 515 copies/ml) during up to 29 months following acute infection. CONCLUSION: These data demonstrate that host genetic factors can influence the clinical manifestations of acute HIV-1 infection and provide a functional link between HLA-B57 and viral immune control.
Authors: Yanhua Tang; Sihong Huang; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; Elizabeth G Ryland; M Anne St John; Rohan Hazra; Celia D C Christie; Margaret E Feeney Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Jacques Fellay; Nicole Frahm; Kevin V Shianna; Elizabeth T Cirulli; Danilo R Casimiro; Michael N Robertson; Barton F Haynes; Daniel E Geraghty; M Juliana McElrath; David B Goldstein Journal: J Infect Dis Date: 2011-01-28 Impact factor: 5.226
Authors: Nicholas J Steers; Jeffrey R Currier; Gustavo H Kijak; Robert C di Targiani; Ashima Saxena; Mary A Marovich; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao Journal: J Virol Date: 2010-11-24 Impact factor: 5.103
Authors: Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker Journal: J Virol Date: 2010-05-26 Impact factor: 5.103
Authors: Daniel G Kavanagh; Daniel E Kaufmann; Sherzana Sunderji; Nicole Frahm; Sylvie Le Gall; David Boczkowski; Eric S Rosenberg; David R Stone; Mary N Johnston; Bradford S Wagner; Mohammad T Zaman; Christian Brander; Eli Gilboa; Bruce D Walker; Nina Bhardwaj Journal: Blood Date: 2005-10-25 Impact factor: 22.113
Authors: Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Mikkel Harndahl; Anette Stryhn; Jonathan M Carlson; Catherine Koofhethile; Bram Gerritsen; Can Keşmir; Fabian Chen; Lynn Riddell; Graz Luzzi; Alasdair Leslie; Bruce D Walker; Thumbi Ndung'u; Søren Buus; David A Price; Philip J Goulder Journal: J Immunol Date: 2015-04-24 Impact factor: 5.422
Authors: Karen A O'Connell; Jie Xu; Anna P Durbin; Linda G Apuzzo; Hejab Imteyaz; Thomas M Williams; Stuart C Ray; Joseph B Margolick; Robert F Siliciano; Joel N Blankson Journal: J Infect Dis Date: 2009-12-15 Impact factor: 5.226
Authors: Arne Schneidewind; Yanhua Tang; Mark A Brockman; Elizabeth G Ryland; Jacqueline Dunkley-Thompson; Julianne C Steel-Duncan; M Anne St John; Joseph A Conrad; Spyros A Kalams; Francine Noel; Todd M Allen; Celia D Christie; Margaret E Feeney Journal: J Virol Date: 2009-06-10 Impact factor: 5.103